MDF Announces FAF Success

SAN FRANCISCO, CA (March 28, 2014): MDF has published the results of its first-ever Fund-a-Fellow Program Assessment measuring the impact of the first five years of its post-doctoral fellowship grant program.

A Conversation with Dr. Richard T. Moxley, III

Dr. Richard Moxley, Director of the Wellstone Muscular Dystrophy Cooperative Research Center at the University of Rochester and a global leader in DM clinical care and research recently talked with MDF about his long and exceptionally distinguished career in neurology.

The Mef2 Transcription Network is Disrupted in DM Heart Tissue

Researchers at important academic labs around the US have recently published exciting new information about advances in DM research.

Structure of the Myotonic Dystrophy Type 2 RNA

Researchers at important academic labs around the US have recently published exciting new information about advances in DM research.

MDF Grant Recipient Develops Tool for Measuring the Impact of Childhood DM on Quality of Life

To support our commitment to DM research, MDF awards fellowship grants to postdoctoral researchers as part of our annual Fund-A-Fellow (FAF) program. We recently caught up with one of our current grant recipients, Dr. Nicholas Johnson, Assistant Professor of Neurology at the University of Utah.

Key DM Research Discoveries

Timeline of key discoveries in myotonic dystrophy research since DM was first described in 1909.

Impact of Childhood and Congenital DM on Quality of Life

Nicholas Johnson, MD, and researchers at the University of Rochester recently published an article in The Journal of Child Neurology that describes the impact of childhood and congenital myotonic dystrophy on quality of life.

A New Study Provides Hope for DM Treatments

Maurice Swanson, Ph.D., Professor of Molecular Genetics and Microbiology at University of Florida, Gainesville, and a team of researchers have found that the muscleblind-like 2 (MBNL2) protein in the central nervous system (CNS) may be responsible for the neurological impacts of myotonic dystrophy

Ritalin Could Curb Excessive Daytime Sleepiness

Methylphenidate, a psycho-stimulant drug, also known by its 1948 trademarked name of Ritalin, could be useful in the treatment of excessive daytime sleepiness (EDS) for DM1 patients, according to a recent study conducted by The Department of Human Genetics at the Centre Hospitalier Universitaire de Quebec in Quebec City, Canada.

MDF Awards $200,000 for Research into Treatments for DM

MDF is pleased to announce its most recent round of Fund-A-Fellow postdoctoral fellowship research grant awards. In January 2013, MDF awarded two $100,000 grants to postdoctoral Fellows working in universities and research facilities

© Myotonic Dystrophy Foundation. All rights reserved.